Proteases inhibition assessment on PC12 and NGF treated cells after oxygen and glucose deprivation reveals a distinct role for aspartyl proteases.
Hypoxia is a severe stressful condition and induces cell death leading to neuronal loss both to the developing and adult nervous system. Central theme to cellular death is the activation of different classes of proteases such as caspases calpains and cathepsins. In the present study we investigated the involvement of these proteases, in the hypoxia-induced PC12 cell death. Rat PC12 is a model cell line for experimentation relevant to the nervous system and several protocols have been developed for either lethal hypoxia (oxygen and glucose deprivation OGD) or ischemic preconditioning (IPS). Nerve Growth Factor (NGF) treated PC12 differentiate to a sympathetic phenotype, expressing neurites and excitability. Lethal hypoxia was established by exposing undifferentiated and NGF-treated PC12 cells to a mixture of N(2)/CO(2) (93:5%) in DMEM depleted of glucose and sodium pyruvate for 16 h. The involvement of caspases, calpains and lysosomal cathepsins D and E to the cell death induced by lethal OGD was investigated employing protease specific inhibitors such as z-VAD-fmk for the caspases, MDL28170 for the calpains and pepstatin A for the cathepsins D and E. Our findings show that pepstatin A provides statistically significant protection from cell death of both naive and NGF treated PC12 cells exposed to lethal OGD. We propose that apart from the established processes of apoptosis and necrosis that are integral components of lethal OGD, the activation of cathepsins D and E launches additional cell death pathways in which these proteases are key partners.
Laboratory of Physiology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. kritis@med.auth.gr
Aristidis
A
Kritis
Chryssa
C
Pourzitaki
Ioannis
I
Klagas
Michael
M
Chourdakis
Maria
M
Albani
D000818:Animals; D057055:Aspartic Acid Proteases / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D002154:Calpain / Q000037:antagonists & inhibitors / Q000378:metabolism; D061945:Caspase Inhibitors; D020169:Caspases / Q000378:metabolism; D002403:Cathepsins / Q000037:antagonists & inhibitors / Q000378:metabolism; D016923:Cell Death / Q000187:drug effects; D015687:Cell Hypoxia / Q000187:drug effects; D004347:Drug Interactions; D005947:Glucose / Q000172:deficiency*; D008247:Lysosomes / Q000187:drug effects / Q000201:enzymology; D020932:Nerve Growth Factor / Q000494:pharmacology*; D010100:Oxygen / Q000378:metabolism*; D016716:PC12 Cells; D011480:Protease Inhibitors / Q000494:pharmacology*; D051381:Rats
D061945:Caspase Inhibitors; D011480:Protease Inhibitors; D020932:Nerve Growth Factor; D057055:Aspartic Acid Proteases; D002403:Cathepsins; D002154:Calpain; D020169:Caspases; D005947:Glucose; D010100:Oxygen